The gut-microbiome-neurodegeneration axis represents one of the most dynamic and rapidly evolving research frontiers in understanding the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and related neurodegenerative disorders. This axis encompasses the bidirectional communication network between the intestinal microbiome—a community of approximately 38 trillion microorganisms—and the central nervous system, mediated through microbial metabolites, immune signaling, neural pathways, and endocrine mechanisms. Unlike the more general "gut-brain axis," this axis specifically focuses on how the composition, function, and metabolites of the gut microbiome directly influence neurodegenerative processes, and how neurodegeneration, in turn, alters gut microbial ecology. The microbiome's remarkable plasticity—as a modifiable environmental factor—makes this axis a particularly attractive target for therapeutic intervention in diseases that have historically lacked disease-modifying treatments.
The gut-microbiome-neurodegeneration axis represents one of the most dynamic and rapidly evolving research frontiers in understanding the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and related neurodegenerative disorders. This axis encompasses the bidirectional communication network between the intestinal microbiome—a community of approximately 38 trillion microorganisms—and the central nervous system, mediated through microbial metabolites, immune signaling, neural pathways, and endocrine mechanisms. Unlike the more general "gut-brain axis," this axis specifically focuses on how the composition, function, and metabolites of the gut microbiome directly influence neurodegenerative processes, and how neurodegeneration, in turn, alters gut microbial ecology. The microbiome's remarkable plasticity—as a modifiable environmental factor—makes this axis a particularly attractive target for therapeutic intervention in diseases that have historically lacked disease-modifying treatments.
The recognition that the gut microbiome undergoes substantial and reproducible alterations in neurodegenerative diseases has shifted the field from viewing these changes as epiphenomena to actively investigating the microbiome as a potential causal contributor to disease pathogenesis. Studies in germ-free mice, antibiotic-treated mice, and fecal microbiota transplantation (FMT) models have provided causal evidence that microbiome composition directly influences neuroinflammation, protein aggregation, and behavioral outcomes in animal models of PD and AD. The discovery that specific microbial metabolites, such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs), can cross the blood-brain barrier and directly modulate glial cell function has revealed mechanistic pathways through which gut bacteria influence neurodegeneration. Furthermore, the identification of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) as a critical link between microglial immunity and the gut microbiome has opened entirely new avenues for understanding how peripheral microbial signals shape brain immune responses.
The gut microbiome in PD exhibits reproducible compositional shifts that correlate with disease severity and progression. Meta-analyses of over 20 case-control studies have identified a consistent dysbiosis pattern characterized by reduced microbial diversity, decreased abundance of Prevotellaceae and Lachnospiraceae families, and increased levels of Enterobacteriaceae[@chen2022]. The decrease in butyrate-producing bacteria is particularly noteworthy, as butyrate is a critical short-chain fatty acid with potent anti-inflammatory and gut barrier-stabilizing properties. Notably, these microbiome alterations are detectable in early-stage PD patients, often preceding the onset of motor symptoms, suggesting that gut dysbiosis may be an early pathogenic event rather than a consequence of neurodegeneration.
Specific bacterial genera showing altered abundance in PD include reduced Faecalibacterium, Roseburia, Blautia, and Prevotella, while Akkermansia muciniphila, Lactobacillus, and Bifidobacterium are often increased[@sampson2020]. The enrichment of mucin-degrading Akkermansia is consistent with the observation that PD patients exhibit increased intestinal permeability, allowing bacterial products and metabolites to cross the gut barrier into systemic circulation. Notably, constipation—a hallmark prodromal symptom of PD—is closely linked to microbiome alterations, and the severity of constipation correlates with specific microbiome signatures.
AD patients similarly exhibit reproducible gut microbiome alterations, though the pattern differs somewhat from PD. Studies have documented reduced microbial diversity, decreased Bifidobacterium and Faecalibacterium, and increased Bacteroides and Alistipes in AD cohorts[@vogt2017]. The gut microbiome in AD shows a shift toward pro-inflammatory configurations, with increased abundance of pro-inflammatory taxa such as Escherichia/Shigella and decreased anti-inflammatory species such as Firmicutes[@chen2020]. These alterations correlate with peripheral inflammatory markers including IL-6, IL-1β, and TNF-α, suggesting a gut-driven contribution to the chronic neuroinflammation that characterizes AD pathology.
The fecal microbiome of AD patients contains higher levels of Gram-negative bacteria capable of producing lipopolysaccharide (LPS), and circulating LPS levels are elevated in both AD patients and animal models of amyloid pathology. Curiously, several bacterial species produce amyloid-like proteins (e.g., curli fibers from E. coli) that may cross-seed amyloid-beta and alpha-synuclein aggregation in the brain, providing a potential mechanistic link between gut bacteria and proteinopathy.
SCFAs—primarily acetate, propionate, and butyrate—are the principal metabolites produced by bacterial fermentation of dietary fiber in the colon. These fatty acids serve as the primary energy source for colonocytes, maintain intestinal barrier integrity, and exert systemic effects including modulation of neuroinflammation[@kelly2019]. Butyrate is particularly notable as a potent histone deacetylase (HDAC) inhibitor that can modulate gene expression in immune cells and neurons. In the gut, SCFAs strengthen the intestinal epithelial barrier, reduce gut permeability, and promote regulatory T cell differentiation. In the brain, SCFAs cross the blood-brain barrier and influence microglial maturation, phenotype, and function.
In neurodegeneration, SCFA deficiency has been consistently observed in both PD and AD. Reduced butyrate-producing bacteria in PD patients correlates with motor symptom severity, and supplementation with butyrate or SCFA mixtures has shown beneficial effects in mouse models of PD, reducing microglial activation and improving motor performance[@cryan2019]. SCFAs modulate microglial function through GPR41/GPR43 receptor signaling and epigenetic mechanisms, promoting an anti-inflammatory, neuroprotective phenotype. The protective effects of SCFAs include reduced amyloid-beta production, enhanced phagocytic clearance of pathological proteins, and suppression of pro-inflammatory cytokine production by activated microglia.
The therapeutic potential of SCFA supplementation is limited by the pharmacokinetic challenge of delivering these volatile compounds to the brain. Butyrate has poor oral bioavailability due to rapid absorption in the colon, and systemic administration achieves low brain concentrations. Novel delivery approaches under investigation include histone deacetylase inhibitor prodrugs, SCFA-releasing microparticles, and microbiome-targeted strategies that enhance endogenous SCFA production.
TMAO is a gut microbiota-dependent metabolite generated through a two-step process: gut bacteria convert dietary choline, carnitine, and phosphatidylcholine to trimethylamine (TMA), which is then oxidized in the liver by flavin-containing monooxygenases (FMO3) to TMAO[@bhattarai2024]. Elevated circulating TMAO has emerged as a significant risk factor for cardiovascular disease, but recent evidence strongly implicates TMAO in neurodegenerative processes as well. Studies have demonstrated elevated plasma TMAO levels in PD patients compared to healthy controls, and higher TMAO concentrations correlate with more severe motor symptoms and cognitive impairment[@zhao2023].
The mechanisms through which TMAO promotes neurodegeneration are multifaceted. TMAO promotes microglial activation and neuroinflammation through NF-κB signaling pathway upregulation. It exacerbates mitochondrial dysfunction by impairing Complex I activity and increasing oxidative stress in dopaminergic neurons. TMAO also promotes alpha-synuclein aggregation by increasing neuronal oxidative stress and protein aggregation propensity. In mouse models, chronic TMAO administration accelerates motor deficits, increases alpha-synuclein pathology in the substantia nigra, and enhances microglial activation, while TMAO reduction (via dietary intervention or antibiotic modulation) attenuates these effects.
The demonstration that TMAO can directly influence alpha-synuclein pathology in the brain has made it an attractive therapeutic target. Strategies under investigation include dietary modification to reduce TMAO precursors, modulation of the gut microbiome to decrease TMA-producing bacteria, and direct inhibition of FMO3 to reduce hepatic TMAO synthesis.
LPS is a major component of the outer membrane of Gram-negative bacteria, and elevated circulating LPS is a hallmark of gut dysbiosis and increased intestinal permeability[@chen2022]. When LPS crosses the compromised gut barrier into systemic circulation, it triggers systemic inflammation through activation of Toll-like receptor 4 (TLR4) on immune cells, including microglia in the brain. LPS-induced neuroinflammation is a well-characterized model of PD-like pathology in rodents, where intracerebral or peripheral LPS administration reproduces key features including microglial activation, dopaminergic neuron loss, and motor deficits.
In human neurodegeneration, elevated circulating LPS has been documented in both AD and PD patients, and LPS colocalizes with amyloid plaques and neurofibrillary tangles in AD brains. LPS binds to CD14 and MD-2 coreceptors on microglia, triggering MyD88-dependent signaling cascades that activate NF-κB and MAP kinases, resulting in production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). Chronic low-grade LPS exposure from the gut creates a persistent pro-inflammatory state that primes microglia for exaggerated responses to secondary insults, lowering the threshold for neurodegeneration in response to protein aggregation, oxidative stress, or other challenges.
Therapeutic strategies targeting LPS-mediated inflammation include neutralizing antibodies, LPS-binding protein antagonists, and gut barrier restoration approaches. The recognition that gut-derived LPS contributes to neuroinflammation has also motivated interest in gut-permeability reduction as a neuroprotective strategy.
The intestinal epithelial barrier is a critical interface between the luminal microbiome and the host immune system. This barrier consists of a single layer of epithelial cells connected by tight junctions, adherens junctions, and desmosomes, with an overlying mucus layer that physically separates bacteria from the epithelium. In neurodegeneration, substantial evidence points to a "leaky gut" phenomenon where intestinal permeability is increased, allowing bacterial products and metabolites to cross into systemic circulation[@dodiya2019].
Multiple mechanisms contribute to gut barrier dysfunction in neurodegenerative diseases. Zonulin, a regulator of tight junction permeability, is elevated in PD and AD patients, indicating active disruption of tight junction integrity. Zonulin is triggered by bacterial colonization and dietary factors, linking microbiome composition to barrier function. Alterations in the mucus layer—including reduced mucin production and changes in mucin composition—compromise this first line of defense. Furthermore, dysbiosis itself can directly disrupt tight junctions through bacterial proteases and metabolic products that alter epithelial cell signaling.
The passage of bacterial products across the leaky gut barrier triggers a cascade of systemic effects relevant to neurodegeneration. Bacterial components (LPS, peptidoglycan, flagellin) enter portal circulation and reach the liver, where they induce hepatic inflammation and compromise the liver's detoxification capacity. Circulating endotoxins reach the brain through multiple routes: directly across the BBB at regions of increased permeability, through transport by immune cells, and via the vagus nerve. The liver-brain axis adds another layer of complexity, as hepatic inflammation and compromised liver function impair the clearance of neurotoxic metabolites that would normally be processed and eliminated.
Microbial metabolites that cross the barrier include SCFAs (beneficial), TMAO and LPS (harmful), and various other bacterial products with bioactive properties. The net effect depends on the balance between these metabolites—a shift toward TMAO and LPS with reduced SCFAs creates a pro-inflammatory, pro-aggregation milieu that favors neurodegeneration. This metabolic imbalance provides a mechanistic framework for understanding how gut dysbiosis contributes to brain pathology.
The convergence of gut barrier dysfunction, microbiome dysbiosis, and immune system activation creates a self-reinforcing triad that drives neurodegenerative processes[@main2023]. Gut-derived inflammation primes peripheral immune cells, which then infiltrate the CNS and contribute to neuroinflammation. Activated microglia, in turn, release cytokines that further disrupt the gut barrier, perpetuating the cycle. TREM2 on microglia serves as a critical interface in this triad, as it senses lipid-based signals from both microbial and host sources and directs microglial responses accordingly.
The hypothesis that alpha-synuclein (αSyn) pathology originates in the gut before spreading to the brain is one of the most influential frameworks in PD research[@sampson2016]. Originally proposed by Heiko Braak and colleagues, this "dual-hit" hypothesis posits that an unknown pathogen enters the body through the nasal or gastrointestinal route, triggers αSyn aggregation in the enteric nervous system (ENS), and then propagates retrogradely to the CNS via the vagus nerve. This hypothesis is strongly supported by the observation that αSyn-positive inclusions appear in the ENS and vagus nerve in early-stage PD, often years before motor symptoms develop.
Evidence for gut-to-brain propagation of αSyn is extensive and includes experimental studies in which αSyn preformed fibrils injected into the gut wall of rodents propagate to the brain via the vagus nerve, producing PD-like motor symptoms and pathology. Similarly, gut bacteria from PD patients transplanted into alpha-synuclein-overexpressing mice accelerates motor deficits and neuroinflammation, while germ-free or antibiotic-treated mice show reduced pathology. These studies establish that the gut microbiome can directly modulate the initiation and propagation of αSyn pathology.
The process of αSyn seeding from the gut involves multiple steps. First, an initiating event—genetic susceptibility, environmental toxin exposure, or microbiome dysbiosis—triggers αSyn misfolding in enteric neurons. Gut bacteria contribute to this initiation both through direct interactions (eacterial amyloid cross-seeding, LPS-induced inflammation) and indirect effects (SCFA deficiency, gut permeability). The misfolded αSyn then propagates within the ENS through trans-synaptic spreading, moving from neurons in the myenteric plexus to those in the vagus nerve. Vagal afferents carry the pathology to the dorsal motor nucleus of the vagus in the brainstem, from where it spreads rostrally to the substantia nigra and other brain regions.
The concept of "soil" versus "seed" is relevant here: the gut microbiome may act as the "soil" that either facilitates or inhibits αSyn aggregation and propagation. A pro-inflammatory, SCFA-deficient microbiome creates a permissive soil for αSyn seeding, while a healthy, anti-inflammatory microbiome is protective. This framework suggests that microbiome modulation could alter the soil to prevent or slow the propagation of pathology, even if the initial seed is not eliminated.
The clinical evidence for gut-origin PD includes the observation that gastrointestinal symptoms—particularly constipation—precede motor symptoms by up to two decades in a substantial proportion of PD patients[@schrack2024]. The severity of constipation correlates with subsequent motor symptom severity, and patients with inflammatory bowel disease have an increased risk of developing PD. Epidemiologic studies have shown that truncal vagotomy (surgical removal of the vagus nerve trunk) is associated with a reduced risk of PD, supporting the importance of vagal communication in disease development. Studies of appendectomy have yielded mixed results, though the appendix—rich in αSyn-positive neurons—has been implicated as a potential early site of pathology.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor expressed primarily on microglia in the CNS and on macrophages and dendritic cells in peripheral tissues, including the gut[@lin2025]. TREM2 recognizes lipid-based ligands, including apolipoproteins, lipoproteins, and bacterial lipids such as LPS. Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP) to activate PI3K and Syk pathways, promoting microglial survival, proliferation, phagocytosis, and metabolic fitness. TREM2 is critical for the microglial response to neurodegeneration: TREM2-deficient mice show impaired clearance of myelin debris, amyloid plaques, and dead cells, and human TREM2 variants are associated with increased AD risk.
The discovery that TREM2 recognizes bacterial lipids and influences gut immune responses has revealed a direct link between the microbiome and CNS immunity[@lin2025]. In the gut, TREM2 is expressed by intestinal macrophages and influences the response to bacterial challenge. TREM2-deficient mice exhibit altered gut immune responses and changes in microbiome composition, suggesting bidirectional cross-talk between TREM2 signaling and the microbiome. Conversely, the gut microbiome influences TREM2 expression and function through microbial metabolites and endotoxin exposure.
In the brain, TREM2 is essential for the microglial response to protein aggregates, and its function is modulated by signals from the gut microbiome[@main2023]. A pro-inflammatory microbiome (high LPS, low SCFAs) may prime or dysregulate TREM2-dependent microglial responses, impairing the clearance of αSyn and Aβ. In AD, TREM2 variants that reduce receptor function impair the microglial response to amyloid plaques, allowing plaque accumulation and spread. In PD, TREM2 expression in microglia is upregulated in response to αSyn pathology, and this upregulation is necessary for an effective phagocytic response—but if the microbiome dysregulates TREM2 signaling, this protective response may be impaired.
Recent work has demonstrated that TREM2 deficiency itself drives gut dysbiosis and accelerates alpha-synuclein pathology in mouse models of PD[@lin2025]. TREM2-deficient animals show altered microbiome composition, increased gut permeability, and accelerated αSyn pathology in both the gut and the brain. This suggests that TREM2 acts as a hub integrating signals from the gut microbiome with the brain's immune response to neurodegeneration. Therapeutic strategies that enhance TREM2 function or modulate its lipid ligands could address both the microbiome-immune interface and the direct clearance of protein aggregates.
Probiotic formulations containing specific bacterial strains have shown promise in both preclinical and clinical studies for neurodegenerative diseases[@westfall2024]. Lactobacillus and Bifidobacterium species can restore gut barrier function, reduce systemic inflammation, and modulate the gut-brain axis through SCFA production, GABA synthesis, and immune modulation. Multi-strain probiotics have demonstrated modest improvements in cognitive function in AD patients and motor symptoms in PD patients in randomized controlled trials. Prebiotics (dietary fibers that selectively promote beneficial bacteria) aim to enhance endogenous SCFA production and restore a healthy microbiome ecosystem.
Akkermansia muciniphila supplementation has emerged as a particularly promising approach, given that A. muciniphila restores gut barrier function, reduces systemic inflammation, and has shown efficacy in preventing alpha-synuclein propagation in mouse models[@zheng2024]. The mucin-degrading capacity of A. muciniphila actually strengthens the gut barrier by stimulating mucus production, reducing LPS translocation, and promoting anti-inflammatory immune responses. Human trials of pasteurized A. muciniphila are underway for metabolic syndrome and obesity, with potential applications in neurodegeneration.
FMT transfers stool from a healthy donor to a patient, with the goal of restoring a healthy microbiome ecosystem. FMT from young or healthy donors to animals with neurodegeneration improves motor symptoms, reduces neuroinflammation, and decreases protein pathology. Clinical trials of FMT in PD patients have shown mixed results: the GUT-PARFECT trial demonstrated mild but sustained improvements in motor symptoms, while other trials showed safety but limited efficacy. The variability in FMT outcomes likely reflects the complexity of the microbiome, donor variability, and patient-specific factors. Ongoing trials are optimizing FMT protocols including donor selection, preparation methods, and patient stratification.
Diet is the primary modulator of the gut microbiome, and dietary interventions offer a non-pharmacological approach to modifying the gut-microbiome-neurodegeneration axis. The Mediterranean diet—rich in fiber, polyphenols, and omega-3 fatty acids—is associated with increased microbial diversity, higher SCFA production, and reduced neuroinflammation. The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) specifically targets brain health through dietary modification. Ketogenic diets alter the microbiome through changes in bile acid metabolism and may benefit mitochondrial function in neurons. Reducing TMAO precursors (choline from red meat, phosphatidylcholine from eggs) is another dietary approach under investigation.
Direct modulation of TREM2 function and its lipid ligands offers a novel therapeutic approach[@lin2025]. Agonist antibodies that enhance TREM2 signaling are in development for AD and potentially PD. Lipid-based interventions that provide TREM2 ligands—including omega-3 fatty acids and other lipid species—may enhance microglial function. The intersection of gut microbiome and TREM2 suggests that microbiome modulation could be used to optimize the lipid environment for TREM2 activation, combining microbiome-targeted and immunometabolic approaches.
The gut-microbiome-neurodegeneration axis intersects with numerous other neurodegenerative mechanisms:
The gut-microbiome-neurodegeneration axis represents a critical and rapidly expanding area of research at the intersection of microbiology, immunology, and neuroscience. Key takeaways:
Understanding and therapeutically targeting this axis offers the possibility of disease-modifying interventions for neurodegenerative diseases through the manipulation of a modifiable environmental factor.
Related Hypotheses: